Azitra Secures U.S. Patent for Lead Netherton Syndrome Therapy ATR-12

Event summary

  • Azitra received U.S. Patent 12,606,610 B2 on April 21, 2026, covering ATR-12, an engineered strain of S. epidermidis expressing LEKTI protein fragments for Netherton syndrome treatment.
  • ATR-12 is currently in a Phase 1b clinical trial for Netherton syndrome, a rare skin disease affecting ~20,000 patients globally.
  • The patent protects microbes secreting LEKTI protein domains and methods for treating skin diseases, including Netherton syndrome.
  • Azitra's pipeline includes ATR-04 for EGFR inhibitor-associated rash, with FDA Fast Track designation.

The big picture

Azitra's new patent fortifies its lead in developing live biotherapeutic products for rare skin diseases, a niche with high unmet medical need. The patent protection comes as the company advances its Phase 1b trial for ATR-12, positioning it as a potential first-in-class therapy for Netherton syndrome. The strategic move underscores Azitra's focus on leveraging microbial genetic engineering to address dermatological conditions with limited treatment options.

What we're watching

Clinical Progress
Whether ATR-12's Phase 1b trial will demonstrate sufficient efficacy to advance to later-stage studies.
IP Strategy
How Azitra will leverage this patent to strengthen its competitive position in precision dermatology.
Pipeline Expansion
The pace at which Azitra can advance its ATR-04 program and other pipeline candidates.